What makes a fungal infection 'invasive'?

It is invasive when fungi move beyond skin and mucosal surfaces into normally sterile sites such as the bloodstream or deep tissues, in contrast to superficial colonization; in the ICU the commonest invasive form is invasive candidiasis, including candidaemia.

Why are invasive fungal infections often diagnosed late in the ICU?

Blood cultures for Candida are relatively insensitive and the signs overlap with bacterial sepsis, so invasive fungal infection can be difficult to confirm early, which contributes to its high mortality and to interest in risk scores and non-culture markers.

Invasive Fungal Infections in ICU

Invasive fungal infections are infections in which fungi penetrate beyond mucosal and skin surfaces into normally sterile tissue or the bloodstream. In the intensive care unit they occur chiefly in patients with prolonged stays, broad-spectrum antibiotic exposure, central venous catheters, and impaired host defences, with invasive candidiasis being the most frequent form and invasive mould infections such as aspergillosis arising in selected hosts.

Leia teema tööriistaga PaperMindPeagiFind papers & topics

Tools & resources

Laadi slaidid alla

Learn & explore

VideoPeagi

Definition

An invasive fungal infection is the presence and multiplication of fungi within normally sterile sites - including the bloodstream (fungaemia), deep tissues, or organs - as distinct from superficial colonization of skin or mucosa; in the ICU the predominant example is invasive candidiasis, including candidaemia.

Scope

This topic covers the main invasive mycoses encountered in critical care, the host and care-related factors that predispose to them, the difficulty of timely diagnosis, and why they matter to stewardship and outcomes. It treats invasive fungal infection as a clinical entity at the conceptual level and is reference material; it does not provide diagnostic thresholds, antifungal selection, or treatment regimens.

Core questions

Which critically ill patients are at risk of moving from fungal colonization to invasive infection?
Why is invasive candidiasis difficult to diagnose promptly in the ICU?
How does antibiotic and device exposure relate to invasive fungal risk?
How is invasive (deep) fungal infection distinguished from harmless colonization?

Key concepts

Invasive candidiasis and candidaemia
Colonization versus invasion
Invasive mould infection (e.g., aspergillosis)
Host immunosuppression and risk factors
Central venous catheter as a portal and focus
Diagnostic uncertainty and non-culture markers
Source control of an infected focus

Mechanisms

Invasive candidiasis typically begins when Candida species that colonize the gut and skin gain access to the bloodstream through disrupted barriers - including intravascular catheters and gastrointestinal mucosal injury - in hosts whose defences are impaired by critical illness, surgery, or immunosuppression; broad-spectrum antibacterial therapy further favours fungal overgrowth by suppressing competing bacterial flora (Kullberg 2015). Invasive mould infections such as aspergillosis arise mainly through inhalation in more profoundly immunocompromised or, increasingly recognized, severely ill hosts. Because blood cultures are insensitive and signs are non-specific, invasive fungal infection is often diagnosed late, which is one reason it carries high mortality (Pappas 2016).

Clinical relevance

Invasive fungal infections in the ICU are associated with high mortality and are easy to miss because their presentation overlaps with bacterial sepsis. This entry explains why they are an important consideration in the critically ill and how the field conceptualizes risk and diagnosis; it is educational reference material and does not offer diagnostic criteria, antifungal choices, dosing, or treatment guidance.

Epidemiology

Candida species are among the more common causes of healthcare-associated bloodstream infection, and invasive candidiasis concentrates in patients with prolonged ICU stays, central venous catheters, broad-spectrum antibiotic exposure, recent abdominal surgery, and parenteral nutrition. The IDSA candidiasis guideline summarizes the at-risk populations and the management framework (Pappas 2016), while Kullberg and Arendrup (2015) review the epidemiology and pathogenesis of invasive candidiasis.

History

Awareness of invasive candidiasis as a major ICU problem grew alongside advances in critical care that allowed sicker patients to survive longer with more invasive support. The 2016 IDSA candidiasis guideline (Pappas 2016) and contemporary reviews (Kullberg 2015) consolidated the modern understanding of who is at risk and how invasive fungal infection should be approached conceptually.

Debates

How should empiric or pre-emptive antifungal therapy be targeted?: Late diagnosis pushes toward treating high-risk patients before confirmation, but most colonized or at-risk patients never develop invasive infection, so risk scores and non-culture markers are used to avoid both undertreatment and indiscriminate antifungal exposure; the optimal triggering strategy remains debated.

Seminal works

kullberg-2015
pappas-2016

Frequently asked questions

What makes a fungal infection 'invasive'?: It is invasive when fungi move beyond skin and mucosal surfaces into normally sterile sites such as the bloodstream or deep tissues, in contrast to superficial colonization; in the ICU the commonest invasive form is invasive candidiasis, including candidaemia.
Why are invasive fungal infections often diagnosed late in the ICU?: Blood cultures for Candida are relatively insensitive and the signs overlap with bacterial sepsis, so invasive fungal infection can be difficult to confirm early, which contributes to its high mortality and to interest in risk scores and non-culture markers.